Topical 5% imiquimod for the therapy of actinic cheilitis - 01/09/11
Abstract |
Background: Tissue-destructive and more selective cytotoxic therapies are the main methods used to treat actinic cheilitis. A topical immune stimulant, 5% imiquimod cream, has recently been used for treatment of cutaneous epithelial malignancies including squamous cell carcinoma in situ and basal cell carcinoma. Objective: Our aim was to review the results in patients who had been treated for actinic cheilitis with imiquimod cream. Methods: A review identified 15 patients with biopsy-proven actinic cheilitis who had been treated with topical imiquimod 3 times weekly for 4 to 6 weeks. All patients with histories consistent with facial herpes simplex or documented prior facial herpes simplex eruptions were treated with oral valcyclovir, 1 g/d, during imiquimod therapy. Results: All 15 patients showed clinical clearing of their actinic cheilitis at 4 weeks after discontinuation of the topical imiquimod. Sixty percent of the patients experienced a moderate to marked increased local reaction consisting of increased erythema, induration, and erosions or ulcerations, which in some cases continued through the period of therapy. Conclusion: Imiquimod appears to have a role in the treatment of actinic cheilitis. However, the dose and duration of therapy, as well as the long-term efficacy, need to be established; and local reactions are to be expected and may not improve during therapy. (J Am Acad Dermatol 2002;47:497-501.)
Le texte complet de cet article est disponible en PDF.Plan
Funding sources: None. |
|
Conflict of interest: None identified. |
|
The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, the Department of the Navy, or the Department of Defense. |
|
Reprint requests: Kathleen J. Smith, MD, Departments of Dermatology and Pathology, University of Alabama at Birmingham, Eye Foundation Hospital, Suite 414, 1720 University Blvd, Birmingham, AL 35294-0009. |
Vol 47 - N° 4
P. 497-501 - octobre 2002 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?